David Rodman
Technik-/Wissenschafts-/F&E-Leiter bei MINERALYS THERAPEUTICS, INC.
Vermögen: 865 128 $ am 30.04.2024
Profil
David M.
Rodman is currently the Chief Medical Officer at Mineralys Therapeutics, Inc. and a Member-Editorial Board at American Thoracic Society, Inc. He previously worked as the Vice President-Clinical Development at Vertex Pharmaceuticals, Inc. from 2011 to 2014, Head-Respiratory Translational Medicine at Novartis Institutes for Biomedical Research, Inc., Executive Vice President-Research & Development at miRagen Therapeutics, Inc., Executive Vice President-Research & Development at ProQR Therapeutics NV, and Chief Medical Officer & Executive VP-Discovery at Nivalis Therapeutics, Inc. from 2016 to 2017.
He also worked as a Professor at The University of Colorado.
Dr. Rodman holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from Haverford College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.05.2024 | 78 363 ( 0,16% ) | 865 128 $ | 30.04.2024 |
Aktive Positionen von David Rodman
| Unternehmen | Position | Beginn |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2021 |
American Thoracic Society, Inc.
 American Thoracic Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Thoracic Society, Inc. is a professional membership organization for thoracic surgeons. The non-profit company is based in New York, NY. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von David Rodman
| Unternehmen | Position | Ende |
|---|---|---|
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Technik-/Wissenschafts-/F&E-Leiter | 15.01.2017 |
| VERTEX PHARMACEUTICALS INCORPORATED | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2014 |
| PROQR THERAPEUTICS N.V. | Technik-/Wissenschafts-/F&E-Leiter | - |
| The University of Colorado | Corporate Officer/Principal | - |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ausbildung von David Rodman
| University of Pennsylvania | Doctorate Degree |
| Haverford College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| PROQR THERAPEUTICS N.V. | Health Technology |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
miRagen Therapeutics, Inc. /Old/
 miRagen Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology miRagen Therapeutics, Inc. develops microRNA-based therapeutics for cardiovascular and muscle diseases. It leverages in-house expertise in miRNA biology, oligonucleotide chemistry, and drug development to evaluate and advance RNA-based technologies and potential drug candidates for its own pipeline and in strategic collaborations. The firm aso focuses on hematological malignancies, fibrosis and neuro inflammation. The company was founded by William S. Marshall, Michael R. Bristow, Marvin H. Caruthers, Bruce Lee Booth and Eric Newell Olson in 2007 and is headquartered in Boulder, CO. | Health Technology |
American Thoracic Society, Inc.
American Thoracic Society, Inc. Miscellaneous Commercial ServicesCommercial Services American Thoracic Society, Inc. is a professional membership organization for thoracic surgeons. The non-profit company is based in New York, NY. | Commercial Services |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Commercial Services |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
